Yuhchyau Chen, M.D., Ph.D.

Awards

2021
Fellow (FASTRO)
Sponsor: American Society for Radiation Oncology

2021
Fellow (FAAWR)
Sponsor: American Association for Women in Radiology

VIEW ALL expand_more

Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Lead Researcher: Yuhchyau Chen

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB IIIA or IIIB non-small cell lung cancer.

View Study Details

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Lead Researcher: Yuhchyau Chen

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

View Study Details

Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

Lead Researcher: Yuhchyau Chen

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.

View Study Details

Genotoxicity Assessment for Patients Receiving Large Field Irradiation

Lead Researcher: Yuhchyau Chen

The purpose of the research study is to evaluate an automated, laser-based technique for measuring DNA damage caused by radiation during cancer treatment in immature red blood cells.

View Study Details

Publications

Journal Articles

6/2022
Khairnar R, DeMora L, Sandler HM, Lee WR, Villalonga-Olives E, Mullins CD, Palumbo FB, Bruner DW, Shaya FT, Bentzen SM, Shah AB, Malone S, Michalski JM, Dayes IS, Seaward SA, Albert M, Currey AD, Pisansky TM, Chen Y, Horwitz EM, DeNittis AS, Feng F, Mishra MV. "Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415." JCO clinical cancer informatics.. 2022 Jun; 6:e2100188.

2022
Bigelow EO; Harris J; Fakhry C; Gillison ML; Nguyen-Tân PF; Rosenthal DI; Frank SJ; Nair SG; Bahig H; Ridge JA; Caudell J; Donaldson C; Clifford BT; Shenouda G; Birrer MJ; Chen Y; Le QT. "Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522". Head Neck. 2022; 44(1): 158-167.

2022
Chen F; Chen X; Ren Y; Weng G; Keng PC; Chen Y; Lee SO. "Retraction Note: Radiation-induced glucocorticoid receptor promotes CD44?+?prostate cancer stem cell growth through activation of SGK1-Wnt/?-catenin signaling". J Mol Med (Berl). 2022; 100(1): 149.

Books & Chapters

2014
Chapter Title: Upper Respiratory and Digestive System: Pharynx, Larynx, and Xerostomia
Book Title: ALERT-Adverse Late Effects of Cancer Treatment
Author List: Mittal B; Chen Y; Eisbruch A
Edited By: Rubin P; Constine LS; Marks LB
Published By: Springer-Verlag 2014 in Berlin Heidelberg

2011
Chapter Title: Translational Research in Lung Cancer
Book Title: Advances in Radiation Oncology in Lung Cancer
Author List: Singh D; Bylund K; Chen Y
Edited By: Jeremic B
Published By: Springer-Verlag GmbH 2011 in Heidelberg

2007
Chapter Title: Advances in Chemoradiation Treatment of Locoregionally Advanced Non-small Cell Lung Cancer
Book Title: Lung Cancer: Translational & Emerging Therapies
Author List: Milano MT, Chen Y
Edited By: Pandya K, Brahmer JU, Hidalgo M
Published By: Taylor and Francis 2007 in New York, NY

VIEW ALL PUBLICATIONS